Loading... Please wait...

Molecular Diagnostics in Infectious Disease Testing

Bookmark and Share
Price:
$3,400.00
Publication Date:
May 2017; Pages: 263


Description


Molecular Diagnostics Infectious Disease Sample

This report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts.

 

TABLE OF CONTENTS

1. Overview 11
1.1 Statement of Report 11
1.2 About This Report 12
1.3 Scope of the Report 12
1.4 Objectives 14
1.5 Methodology 14
1.6 Executive Summary 16

2. Introduction to Molecular Diagnostics for Infectious Disease Testing 26
2.1 Molecular Diagnostics Testing and Opportunities in the Infectious Disease Sector 26
2.2 The Infectious Disease Problem 29
2.3 Impact of the Human Genome Project on Molecular Diagnostics 32
2.4 Opportunities for Molecular and Clinical Diagnostics 32
2.4.1 Companion Diagnostics 34
2.5 Development of Molecular Diagnostics Testing Markets 34
2.6 Molecular Diagnostics Testing Technologies and Platforms 35
2.6.1 Amplification Technologies 35
2.6.1.1 PCR and PCR Derivative Platforms 36
2.6.1.2 Multiple Displacement Amplification 41
2.6.1.3 Multiple Annealing and Looping-Based Amplification Cycles 42
2.6.1.4 Whole Genome Amplification 42
2.6.1.5 Nucleic Acid Sequence-Based Amplification 42
2.6.2 Detection of Amplified Gene Products 43
2.6.2.1 High Resolution Melting Analysis 44
2.6.2.2 Microparticle-Based Flow Cytometry 44
2.6.3 DNA and Oligonucleotide Microarrays and Chips 44
2.6.3.1 Array Comparative Genomic Hybridization 47
2.6.4 Gene Sequencing 47
2.6.4.1 Sanger Sequencing 47
2.6.4.2 Next Generation Sequencing 48
2.6.5 Fluorescence In situ Hybridization 53
2.6.6 PCR Reagents for Clinical Diagnostics 54
2.7 Molecular Diagnostics Technologies for Infectious Disease Testing 54
2.8 Market Drivers and Restraints for Molecular Diagnostics of Infectious Diseases 59
2.8.1 Market Drivers 59
2.8.2 Market Restraints 59
2.9 Market and Technology Trends 60
2.9.1 Market Trends 60
2.9.2 Technology Trends 60
2.10 Strategic Recommendations 61

3. Infectious Disease Diagnostics Molecular Testing Market 62
3.1 Molecular Diagnostics Market Overview 62
3.1.2 Overall Infectious Disease Market Analysis 67
3.2 Molecular Testing for Infectious Disease Diagnostics Market 67
3.3 Infectious Disease Molecular Diagnostic Testing Market Segments 79
3.3.1 HIV 79
3.3.1.1 Disease Background and Statistics 79
3.3.1.2 Overview of HIV Testing Methods 82
3.3.1.2.1 Clinical Diagnostic Screening Tests for HIV 84
3.3.1.2.2 HIV Monitoring Tests 84
3.3.1.2.3 Measuring Viral Loads 84
3.3.1.2.4 Genotyping Assays 85
3.3.1.2.5 Phenotyping Assays 85
3.3.1.3 Instruments and MDx Reagents 87
3.3.1.3.1 Abbott Molecular 87
3.3.1.3.2 Alere (becoming part of Abbott) 89
3.3.1.3.3 Beckman Coulter 89
3.3.1.3.4 bioMérieux 90
3.3.1.3.5 Cepheid 90
3.3.1.3.6 Grifols 91
3.3.1.3.7 Hologic 91
3.3.1.3.8 Qiagen 92
3.3.1.3.9 Roche Diagnostics 92
3.3.1.3.10 Siemens Healthcare Diagnostics 95
3.3.1.3.11 LabCorp 96
3.3.1.4 Market Size 96
3.3.1.4.1 HIV Diagnostic Testing 97
3.3.1.5 HIV Market Challenges and Strategic Recommendations 99
3.3.1.5.1 HIV Molecular Diagnostic Market History 99
3.3.1.6 Market Drivers and Restraints 101
3.3.1.6.1 Market Drivers 101
3.3.1.6.2 Market Restraints 101
3.3.1.7 Market and Technology Trends 101
3.3.1.7.1 Market Trends 101
3.3.1.7.2 Technology Trends 102
3.3.1.8 Strategic Recommendations 102
3.3.2 Hepatitis 103
3.3.2.1 Hepatitis B Virus 104
3.3.2.1.1 Hepatitis B Disease Background and Statistics 104
3.3.2.1.2 Clinical Applications of HBV MDx Testing 105
3.3.2.1.3 MDx Instruments and Reagents for Hepatitis B Detection 106
3.3.2.1.3.1 Abbott 107
3.3.2.1.3.2 Beckman Coulter 108
3.3.2.1.3.3 Grifols 108
3.3.2.1.3.4 Hologic 109
3.3.2.1.3.5 Roche 109
3.3.2.1.3.6 Siemens 109
3.3.2.1.4 Hepatitis B Market Size 110
3.3.2.1.5 HBV Market Challenges and Strategic Recommendations 111
3.3.2.1.5.1 Market Drivers and Restraints 111
3.3.2.1.5.1.1 Market Drivers 111
3.3.2.1.5.1.2 Market Restraints 111
3.3.2.1.6 Market and Technology Trends 111
3.3.2.1.6.1 Market Trends 111
3.3.2.1.6.2 Technology Trends 112
3.3.2.1.7 Strategic Recommendations 112
3.3.2.2 Hepatitis C Virus Testing 112
3.3.2.2.1 Disease Background and Statistics 112
3.3.2.2.2 Instruments and Reagents for Hepatitis C Detection 118
3.3.2.2.2.1 Roche 119
3.3.2.2.2.2 Grifols 120
3.3.2.2.2.3 Siemens 121
3.3.2.2.2.4 Hologic 121
3.3.2.2.2.5 Abbott 122
3.3.2.2.2.6 Beckman Coulter 122
3.3.2.2.2.7 Cepheid 122
3.3.2.2.3 Hepatitis C Market Size 123
3.3.2.2.3.1 HCV Market Share 123
3.3.2.2.4 HCV Market Challenges and Strategic Recommendations 124
3.3.2.2.4.1 Market Drivers and Restraints 124
3.3.2.2.4.1.1 Market Drivers 124
3.3.2.2.4.1.2 Market Restraints 125
3.3.2.2.4.2 Market and Technology Trends 125
3.3.2.2.4.2.1 Market Trends 125
3.3.2.2.4.2.2 Technology Trends 126
3.3.2.2.5 Strategic Recommendations 127
3.3.3 Human Papillomavirus 127
3.3.3.1 Disease Background and Statistics 127
3.3.3.2 Instruments and Reagents for HPV Detection 130
3.3.3.2.1 Hologic 131
3.3.3.2.2 Qiagen 132
3.3.3.2.3 Roche 134
3.3.3.2.4 Cepheid 135
3.3.3.2.5 AutoGenomics 135
3.3.3.2.6 incellDx 135
3.3.3.2.7 Fujirebio 136
3.3.3.2.8 Greiner Bio-one 136
3.3.3.2.9 Becton Dickinson 136
3.3.3.3 HPV Market Size 136
3.3.3.4 Market Challenges and Strategic Recommendations 138
3.3.3.4.1 Market Drivers and Restraints 138
3.3.3.4.1.1 Market Drivers 138
3.3.3.4.1.2 Market Restraints 138
3.3.3.4.2 Market and Technology Trends 138
3.3.3.4.2.1 Market Trends 138
3.3.3.4.2.2 Technology Trends 140
3.3.3.4.3 Strategic Recommendations 140
3.3.4 Influenza Viruses 140
3.3.4.1 Disease Background and Statistics 140
3.3.4.2 Instruments and Reagents for Influenza Detection 143
3.3.4.2.1 Quest Diagnostics 143
3.3.4.2.2 bioMérieux 144
3.3.4.2.3 Cepheid 144
3.3.4.2.4 Hologic 144
3.3.4.2.5 Quidel 145
3.3.4.2.6 Veredus Laboratories 145
3.3.4.2.7 Alere (bought by Abbott) 145
3.3.4.2.8 Luminex 145
3.3.4.2.9 GenMark Diagnostic 146
3.3.4.2.10 Nanosphere 146
3.3.4.2.11 Roche 146
3.3.4.3 Influenza Market Size 146
3.3.4.4 Influenza Market Challenges and Strategic Recommendations 147
3.3.4.4.1 Market Drivers and Restraints 147
3.3.4.4.1.1 Market Drivers 147
3.3.4.4.1.2 Market Restraints 147
3.3.4.4.2 Market and Technology Trends 148
3.3.4.4.2.1 Market Trends 148
3.3.4.4.2.2 Technology Trends 148
3.3.4.4.3 Strategic Recommendations 150
3.3.5 STD Testing (including Chlamydia/Gonorrhea Molecular Diagnostic Testing) 150
3.3.5.1 Disease Backgrounds and STD Statistics 150
3.3.5.1.1 Chlamydia Disease Background and Statistics 152
3.3.5.1.2 Gonorrhea Disease Background and Statistics 153
3.3.5.1.3 Other STD Background and Statistics 155
3.3.5.1.3.1 Herpes Simplex Virus 155
3.3.5.1.3.2 Trichomoniasis 155
3.3.5.2 Instruments and Reagents for STD Detection 156
3.3.5.2.1 Becton Dickinson 156
3.3.5.2.2 Roche Diagnostics 157
3.3.5.2.3 Quest 157
3.3.5.2.4 Hologic 158
3.3.5.2.5 Siemens Healthcare 158
3.3.5.2.6 Abbott 159
3.3.5.2.7 Cepheid 159
3.3.5.2.8 Quidel 159
3.3.5.2.9 Luminex 160
3.3.5.2.10 Qiagen 160
3.3.5.3 Global STD (including Chlamydia/Gonorrhea) Molecular Diagnostic Testing Market 161
3.3.5.3.1 Competitive Structure and Market Share Analysis 161
3.3.5.3.1.1 Market Challenges 162
3.3.5.3.1.2 Market Restraints 162
3.3.5.3.2 Market and Technology Trends 162
3.3.5.3.2.1 Market Trends 162
3.3.5.3.2.2 Technology Trends 163
3.3.5.3.2.3 Strategic Recommendations 163
3.3.6 Tuberculosis 164
3.3.6.1 Disease Background and Description 164
3.3.6.2 Product Analysis: Instruments and Reagents 167
3.3.6.2.1 Veredus Laboratories 167
3.3.6.2.2 Abbott 167
3.3.6.2.3 Seegene 168
3.3.6.2.4 Cepheid 168
3.3.6.3 Method Comparison 168
3.3.6.4 Tuberculosis Market Size 169
3.3.6.5 Competitive Structure and Market Share Analysis 170
3.3.6.6 Market Challenges 171
3.3.6.6.1 Market Drivers 171
3.3.6.6.2 Market Restraints 171
3.3.6.7 Market and Technology Trends 171
3.3.6.7.1 Market Trends 171
3.3.6.7.2 Technology Trends 172
3.3.6.8 Strategic Recommendations 172
3.3.7 Methicillin-Resistant Staphylococcus aureus (MRSA) 173
3.3.7.1 Disease Background and Description 173
3.3.7.2 Product Analysis: Instruments and Reagents 174
3.3.7.2.1 Cepheid 174
3.3.7.2.2 Roche 175
3.3.7.2.3 Becton Dickinson 175
3.3.7.2.4 Molecular Detection, Inc. (MDI) 176
3.3.7.3 MRSA Market Size 176
3.3.7.4 Competitive Structure and Market Share Analysis 177
3.3.7.5 Market Challenges 178
3.3.7.5.1 Market Drivers 178
3.3.7.5.2 Market Restraints 178
3.3.7.6 Market and Technology Trends 178
3.3.7.6.1 Market Trends 178
3.3.7.7 Strategic Recommendations 179
3.3.8 Vancomycin-Resistant Enterococci 180
3.3.8.1 Disease Background and Description 180
3.3.8.2 Assay Kits 182
3.3.9 C. difficile 182
3.3.9.1 Product Analysis: Instruments and Reagents 182

4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 185
4.1 Infectious Disease Diagnostic Tests 185
4.1.1 Molecular Diagnostic Tools Solutions 187
4.1.2 Technology of Gene Expression Analysis 187
4.1.2.1 Amplification and Detection of RNA 187
4.1.2.2 Analysis of Multiple Genes 188
4.1.2.3 Advanced Information Technology 188
4.2 Use of Molecular Tests in Infectious Disease 189
4.2.1 Molecular Screening 189
4.2.2 Early Detection 189
4.2.3 Detection of Specific Resistance Genes and Viral Loading Tests 189
4.2.4 Pharmacogenomics and Personalized Medicine in Molecular Diagnostic Infectious Disease
Testing 190
4.2.5 Molecular Strain Typing 191
4.3 Cost of Molecular Diagnostic Testing 193
4.4 Use of Multiplex PCR Tests 194
4.4.1 Advantages of Multiplex PCR 194
4.4.2 Applications of Multiplex PCR 194
4.5 Next-Generation Sequencing 194
4.6 Patient Flow Software 196
4.7 LAMP 196
4.8 Ion Proton System for Gene Sequencing 196
4.9 xMap Technology (Luminex) 197
4.10 The Invader® Chemistry Platform (Hologic) 198

5. Business 200
5.1 Technology and Market Trends 200
5.1.1 Technology Trends 200
5.1.2 Market Trends and Financial Considerations 203
5.2 M&A Activity 204
5.3 Partnerships 205
5.4 Competitive Analysis 206
5.4.1 Primary Competitors 206
5.4.2 Industry Challenges and Strategic Recommendations 207
5.4.3 Commercialization of Molecular Diagnostic Products 208
5.5 Intellectual Property Rights 208
5.5.1 Patents 209
5.6 Opportunities and Strategic Recommendations 210
5.6.1 The Key Technical Opportunities with Significant Market Appeal in the Molecular Diagnostic Space in the Next Five Years 210
5.6.2 Developments for Molecular Diagnostic Instrumentation Products 211
5.6.3 Market Penetration Strategies for Infectious Disease Testing 211
5.7 Commercial Manufacturing of Molecular Diagnostics Infectious Disease Products: Requirements 211
5.7.1 Elements of Commercial Manufacturing 211
5.7.1.1 Regulatory Requirements 211
5.7.1.2 Manufacturing Process Scale 212
5.7.1.3 In-House Manufacturing 212
5.7.2 Contract Manufacturing: Commercial and Academic 213
5.7.3 Sales and Marketing Strategies for Infectious Disease Tests 214

6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 217
6.1 Overview 217
6.1.1 Gap Filling 217
6.2 Trends in Reimbursement Practice 218
6.2.1 Medicare Reimbursement Threats 219
6.2.2 Analysis of ROI for Molecular Diagnostic Tests for Infectious Disease Using Current Medicare Reimbursement Rules 220
6.3 Trends in Patient Care and Reimbursement 221
6.4 Revenue Threats 222
6.4.1 Medicare Payment Exceptions 223
6.4.2 Three Areas for Denial of Claims 224
6.5 Billing Rules 224
6.5.1 Medicare Billing Procedures 225

7. Regulatory Requirements 226
7.1 Food and Drug Administration 226
7.2 CLIA Regulations 226
7.3 Clinical Laboratory Improvement Act 227
7.4 State Licensing for Service Laboratories 228
7.5 IVDMIAs 228
7.6 FDA Draft Guidance on In Vitro Companion Diagnostic Devices 230
7.7 510(k) Clearance 230
7.8 Pre-Market Approval 231
7.8.1 Pre-Market Approval Application 231
7.9 Analyte Specific Reagents 232
7.9.1 Laboratory Developed Tests 233
7.10 What Regulatory Guidance is Needed for Companion Biomarkers? 234
7.11 U.S. Patent and Trademark Office 235
7.12 IRB Approval in Clinical Trials 235
7.13 CE Marking and the European In Vitro Diagnostic Device Directive 236
7.14 De Novo Classification 236
7.15 Research Use Only Reagents 236
7.16 FDA Recommendations on MRSA and SA Testing 236
7.17 FDA Guidance on Molecular Diagnostic Instruments with Combined Functions 237

8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 240
8.1 What are Key Opportunities in Infectious Disease Testing Development and Commercialization? 240
8.2 What are the Current Obstacles for Molecular Diagnostic Infectious Disease Testing Implementation? 240
8.3 How do Business Strategies, Such as Those Relating to Acquisition, Drive Molecular Diagnostic Strategies? 240
8.4 How might Novel Infectious Disease Molecular Diagnostic Test Development Lead to Acquisition Strategies and their Implications for Deal Making? 241
8.5 How can Molecular Diagnostic Tests Increase Value in an Associated Drug Marketing Plan? 241
8.6 Which Types of Infectious Disease Molecular Diagnostic Testing should be Developed by Diagnostic Companies at Various Stages in the Development Pipeline? 242
8.7 How can Regulatory Oversight Drive Approval and Adoption of New Technologies? 242
8.8 How will Platform Technology Companies Enter the Space? 242
8.9 Will Pharma Integrate with Diagnostics? 243
8.10 How do Platform Technology Companies Position Themselves for Diagnostics Development? 244
8.11 Evaluate How Partnering and M&As will Alter the Competitive Landscape 244
8.12 How can Big Pharma and Diagnostic Companies Co-Develop Biomarkers in a Model for Regulatory Acceptance? 245
8.13 How to Maximize Business Development Through Biomarker Strategies? 245
8.14 What is the Best Type of Business Model for Developing Genetic Biomarkers for Infectious Disease? 246
8.15 How Best have Genetic Biomarkers Provided the Most Benefit in Infectious Disease Testing? 246
8.16 What are the Most Innovative Methods in Development of Molecular Diagnostic Biomarkers? 246
8.17 What are the Best Values for Genetic Biomarkers in Drug Development and in Diagnostics? 246

9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 248
9.1 Resistance and Antibiotic Usage 250
9.2 Infection Control Programs 252

10. Company Profiles 253
10.1 Abbott Laboratories 253
10.2 AdvanDx 254
10.3 Affymetrix 254
10.4 AutoGenomics, Inc. 255
10.5 Beckman Coulter 256
10.6 Becton, Dickinson and Company 256
10.7 bioMérieux 257
10.8 Cepheid 257
10.9 GenMark Diagnostics, Inc. 258
10.10 Genomica S.A.U. 258
10.11 Great Basin Corporation 259
10.12 Grifols 259
10.13 Hologic 259
10.14 Illumina, Inc. 260
10.15 Luminex Corp. 261
10.16 Nanosphere 262
10.17 Qiagen N.V. 263
10.18 Quidel 264
10.19 Roche Diagnostics (Roche Ltd.) 265
10.20 Siemens AG 265
10.21 Veredus Laboratories 266


INDEX OF FIGURES

Figure 2.1: Relationship of DNA Testing to Key Areas of Clinical Diagnosis 26
Figure 2.2: Finding Genes with Microassays 27
Figure 2.3: The Use of Microassays for Studying Gene Expression 28
Figure 2.4: Overall Structure of Nucleic Acid Testing Market 33
Figure 2.5: The PCR Cycle 36
Figure 2.6: Multiple Displacement Amplification 41
Figure 2.7: Using DNA Microassays to Measure Gene Expression 46
Figure 3.1: Global Market for Molecular Diagnostics, 2012-2020 62
Figure 3.2: Global Market for Molecular Diagnostics Testing, 2015 64
Figure 3.3: Share of Molecular Diagnostics Testing by Testing Type, 2015 65
Figure 3.4: Key Players Market Share in Global Molecular Diagnostics Testing Markets, 2015 66
Figure 3.5: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2012-2020 68
Figure 3.6: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2012-2020 69
Figure 3.7: Infectious Disease Testing Revenue Market Share of the Total U.S. Molecular Diagnostics Market,
2010 and 2020 70
Figure 3.8: European Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 71
Figure 3.9: Japanese Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 72
Figure 3.10: Rest of World (ROW) Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 73
Figure 3.11: Infectious Disease Testing Revenue Market Share by Region, 2015 73
Figure 3.12: Total Global Infectious Disease Molecular Diagnostics Markets, 2015 74
Figure 3.13: Total U.S. Infectious Disease Molecular Diagnostics Markets, 2015 75
Figure 3.14: Total Global Infectious Disease Molecular Diagnostics Markets, 2020 76
Figure 3.15: Total U.S. Infectious Disease Molecular Diagnostics Markets, 2020 77
Figure 3.16: Global Population Living with HIV, 2001-2014 79
Figure 3.17: Global View of HIV Infection, 2013 80
Figure 3.18: Top Selling AIDS Drugs, 2014 82
Figure 3.19: CDC Recommendations for HIV Testing in Laboratories, 2014 83
Figure 3.20: Distribution of HIV Molecular Diagnostic Testing by Purpose 97
Figure 3.21: Estimated Market for Global HIV Molecular Diagnostic Testing, 2014-2020 98
Figure 3.22: Estimated Market for U.S. HIV Molecular Diagnostic Testing, 2014-2020 98
Figure 3.23: Global Market Share Viral Load HIV Molecular Diagnostic Testing 99
Figure 3.24: Geographic Distribution of Chronic HBV Infection 105
Figure 3.25: Global Prevalence of Hepatitis C 113
Figure 3.26: Incidence of Acute Hepatitis C in the U.S., 1982-2013 114
Figure 3.27: Primary Causes of Chronic Liver Disease 116
Figure 3.28: Global Market Share of HCV Molecular Diagnostic Market, 2015 124
Figure 3.29: Hybrid Capture 2 (HC2) versus PCR—Analytical Sensitivity and Clinical Sensitivity 133
Figure 3.30: Basic Steps in Hybrid Capture 2 Technology 134
Figure 3.31: Global Market Share Estimates for Molecular Diagnostic HPV Testing, 2015 137
Figure 3.32: Influenza Positive Tests Reported to the CDC, 2015-2016 Season 142
Figure 3.33: Number of Reported and Confirmed Cases of Influenza by Virus Sub-Type Worldwide,
2013 142
Figure 3.34: U.S. Rates of Sexually Transmitted Diseases, 1940-2012 151
Figure 3.35: Reported Cases of Chlamydia in the U.S. by Sex, 1994-2014 153
Figure 3.36: Reported Cases of Gonorrhea in the U.S. by Sex, 1994-2014 154
Figure 3.37: Global Market Share of Chlamydia/Gonorrhea Molecular Diagnostic Market, 2013 161
Figure 3.38: Global Estimated Tuberculosis Incidence Rates, 2014 165
Figure 3.39: Global Market Share of Tuberculosis Molecular Diagnostic Testing 170
Figure 3.40: Global Market Share of MRSA Molecular Diagnostic Market, 2015 177
Figure 3.41: Global Frequency of Vancomycin-Resistant Enterococci, 2006 182
Figure 4.1: Using DNA Microassays to Measure Gene Expression 185
Figure 4.2: Schematic of Molecular Diagnostics for Studying Gene Expression in Patients 186
Figure 4.3: Personalized Medicine in Treatment of Infectious Disease 191
Figure 5.1: FDA Co-Developed Products as a Model for Collaboration 206
Figure 6.1: Reimbursement for Diagnostics in Healthcare Decision Making 218


INDEX OF TABLES

Table 1.1: Market Trends in Infectious Disease DNA Testing 19
Table 1.2: Molecular Diagnostics Infectious Disease Market: Market Drivers Ranked in Order of Impact 20
Table 1.3: Molecular Diagnostics Infectious Disease Market: Market Restraints Ranked in Order of
Impact 20
Table 1.4: Strategic Recommendations on Molecular Diagnostic Sector Business Functions 20
Table 2.1: Top Ten Causes of Death Worldwide, 2012 30
Table 2.2: Prevalent Infectious Diseases Worldwide 31
Table 2.3: Emerging Molecular Diagnostic Technologies 35
Table 2.4: DNA Microarray Applications 45
Table 2.5: Companies Involved in Next Generation Sequencing Platforms 50
Table 2.6: Desired Characteristics for Clinical Versus Discovery Next Generation Sequencing 51
Table 2.7: Automated Molecular Diagnostics Platforms for Infectious Disease Testing 55
Table 2.8: Companies Marketing Products in Molecular Diagnostics Infectious Disease Sector 56
Table 2.9: FDA-Approved Molecular Diagnostic Commercial Kits for the Detection of Infectious Agents 56
Table 2.10: Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 59
Table 2.11: Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 59
Table 2.12: Attractive Growth Areas for Molecular Diagnostic Testing 61
Table 3.1: Global Market for Molecular Diagnostics Testing, 2012-2020 62
Table 3.2: U.S. Market for Molecular Diagnostics Testing, 2012-2020 63
Table 3.3: European Market for Molecular Diagnostics Testing, 2012-2020 63
Table 3.4: Japanese Market for Molecular Diagnostics Testing, 2012-2020 63
Table 3.5: Summary of Molecular Diagnostics Testing Sectors 64
Table 3.6: Share of Global Molecular Diagnostics Testing by Testing Type, 2015 65
Table 3.7: Key Players and Market Share in Global Molecular Diagnostics Testing Market, 2015 65
Table 3.8: Revenue Model for Molecular Diagnostics Testing 66
Table 3.9: Molecular Infectious Disease Diagnostics Market: Market Drivers Ranked in Order of Impact 67
Table 3.10: Molecular Infectious Disease Diagnostics Market: Market Restraints Ranked in Order of
Impact 68
Table 3.11: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2012-2020 68
Table 3.12: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2012-2020 69
Table 3.13: European Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 70
Table 3.14: Japanese Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 71
Table 3.15: Rest of World (ROW) Market Revenue for Molecular Diagnostics Testing for Infectious Disease,
2012-2020 72
Table 3.16: Molecular Diagnostic Markets for Infectious Disease Testing, 2015 74
Table 3.17: Molecular Diagnostic Markets for Infectious Disease Testing, 2020 76
Table 3.18: Business Factors Influencing Advanced Infectious Disease MDx Testing Services 77
Table 3.19: Global Summary of the HIV/AIDS Epidemic, 2014 80
Table 3.20: Global HIV Statistics, 2014 80
Table 3.21: Estimated Number of New HIV Cases in the U.S. by Age, 2014 81
Table 3.22: Top Ten States with New HIV Cases in the U.S., 2014 81
Table 3.21: HIV Resistance Testing Recommendations 86
Table 3.22: Summary of HIV Viral Load, Genotyping, and Donor Screening Molecular Assays 86
Table 3.23: Global Market for Molecular Diagnostic HIV Testing, 2014-2020 97
Table 3.24: U.S. Market for HIV Molecular Diagnostic Testing, 2014-2020 97
Table 3.25: HIV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 101
Table 3.26: HIV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 101
Table 3.27: Estimated Number of New Cases of HBV in the U.S., 2011-2013 105
Table 3.28: Lower Detection Limits of HBV DNA Assays 106
Table 3.29: Clinical Application of Quantitative HBV DNA Testing 106
Table 3.30: Summary of Molecular Diagnostic Assays for Testing HBV 110
Table 3.31: Global Market for HBV Diagnostic Testing, 2014-2020 110
Table 3.32: U.S. Market for HBV Diagnostic Testing, 2014-2020 110
Table 3.33: HBV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 111
Table 3.34: HBV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 111
Table 3.35: Worldwide Rate of HCV Cases 113
Table 3.36: Commercially Available Molecular Diagnostic Products for HCV Assay 118
Table 3.37: Global Market for NAT HCV Diagnostic Testing, 2014-2020 123
Table 3.38: U.S. Market for NAT HCV Diagnostic Testing, 2014-2020 123
Table 3.39: HCV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 124
Table 3.40: HCV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 125
Table 3.41: Recommendations for HCV Diagnostic Testing 127
Table 3.42: Commercially Available Molecular Diagnostic Products for HPV Assay 130
Table 3.43: Global Market for HPV Molecular Diagnostic Testing, 2014-2020 136
Table 3.44: U.S. Market for HPV Molecular Diagnostic Testing, 2014-2020 137
Table 3.45: HPV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 138
Table 3.46: HPV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 138
Table 3.47: Commercially Available Molecular Diagnostic Products for Influenza Assay 143
Table 3.48 Global Market for Influenza Molecular Diagnostic Testing, 2014-2020 146
Table 3.49: U.S. Market for Influenza Molecular Diagnostic Testing, 2014-2020 147
Table 3.50: Influenza Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 147
Table 3.51: Influenza Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 147
Table 3.52: Commercially Available Molecular Diagnostic Assays for STDs 156
Table 3.53: Global Market for STD Molecular Diagnostic Testing, 2014-2020 161
Table 3.54: U.S. Market for STD Molecular Diagnostic Testing, 2014-2020 161
Table 3.55: STD Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 162
Table 3.56: STD Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 162
Table 3.57: Commercially Available Molecular Diagnostic Assays for Testing TB 167
Table 3.58 Global Market for Tuberculosis Molecular Diagnostic Testing, 2014-2020 169
Table 3.59: U.S. Market for Tuberculosis Molecular Diagnostic Testing, 2014-2020 170
Table 3.60: Tuberculosis Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 171
Table 3.61: Tuberculosis Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 171
Table 3.62: Global Market for MRSA Diagnostic Testing, 2014-2020 176
Table 3.63: U.S. Market for MRSA Diagnostic Testing, 2014-2020 177
Table 3.64: MRSA Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 178
Table 3.65: MRSA Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 178
Table 3.66: In Vitro Susceptibility of Staphylococci to New Agents in Development 179
Table 4.1: Key Elements for Business Competition in Molecular Diagnostic Testing for Infectious
Disease 189
Table 4.2: Key Elements for Future Success in Molecular Testing for Infectious Disease 189
Table 4.3: Examples of Personalized Medicine in Treatment of Infectious Disease 191
Table 4.4: Molecular Methods for Epidemiologic Typing of Microorganisms 192
Table 4.5: Drivers of Molecular Diagnostic Methods for Infectious Disease Testing in the Clinical Setting 193
Table 4.6: Barriers to Molecular Diagnostic Methods for Infectious Disease Testing in the Clinical Setting 193
Table 5.1: Technology Trends in Molecular Diagnostic Infectious Disease Testing 200
Table 5.2: Clinical Testing Trends in Molecular Diagnostic Infectious Disease Testing 200
Table 5.3: Business Market Trends in Molecular Diagnostics Infectious Disease Testing 201
Table 5.4: Expected Changes in Healthcare 201
Table 5.5: Lab Customer Feedback for Automated Molecular Diagnostic Instruments 201
Table 5.6: Molecular Diagnostics Infectious Disease Market: Market Drivers Ranked in Order of Impact 202
Table 5.7: Molecular Diagnostics Infectious Disease Market: Market Restraints Ranked in Order of
Impact 202
Table 5.8: Advantages of European Markets for Molecular Diagnostic Testing 203
Table 5.9: Disadvantages of European Markets for Molecular Diagnostic Testing 203
Table 5.10: Summary of Recent M&A Activity in the Molecular Diagnostics Sector 204
Table 5.11: High Value Opportunities in Collaborative and Strategic Partnerships 205
Table 5.12: Principal Competitive Factors in the Molecular Diagnostics Infectious Disease Testing
Market 207
Table 5.13: Molecular Diagnostics Infectious Disease Testing Market: Strategic Recommendations on Molecular Diagnostic Sector Business Functions 207
Table 5.14: Molecular Diagnostics Infectious Disease Market: Impact of Top Industry Challenges
in the U.S. 208
Table 5.15: Documents for Protecting Intellectual Property Rights 209
Table 5.16: Patents Related to PCR, Nucleic Acid Amplification and Sample Prep 210
Table 5.17: Specific Opportunities for Automated Instrumentation and Reagent Systems in Molecular Diagnostics for Infectious Disease Testing 210
Table 5.18: The Required Elements of a Manufacturing Facility 212
Table 5.19: CMO Qualification Audit: Points to Investigate 213
Table 5.20: Strategies and POA for Marketing Infectious Disease Diagnostic Products 214
Table 5.21: Key Elements of Molecular Diagnostic Companies Marketing Plan 215
Table 6.1: Factors Determining Third-Party Payment for Molecular Diagnostic Tests for Infectious
Disease 222
Table 7.1: Regulatory Rules that Affect the Ability of a Diagnostic Testing Reagent Company to Conduct
Business 226
Table 7.2: Strengths of the 510k Process 230
Table 7.3: Drawbacks of the 510k Process 231
Table 7.4: Focus Areas for the FDA Critical Path Initiative 235
Table 8.1: Impediments to Incorporating Promising Molecular Tests into Clinical Practice 247

You Recently Viewed...